Sökning: WFRF:(Remberger Mats) >
Secondary Acute Mye...
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
-
- Nilsson, Christer (författare)
- Karolinska Institutet,Karolinska Institute,Karolinska Inst, Sweden
-
- Hulegårdh, Erik (författare)
- Sahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
-
- Garelius, Hege (författare)
- Sahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
-
visa fler...
-
- Möllgård, Lars (författare)
- Sahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
-
- Brune, Mats (författare)
- Sahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
-
- Wahlin, Anders (författare)
- Umeå University,Umeå universitet,Onkologi,Univ Umea, Dept Radiat Sci, Umea, Sweden
-
- Lenhoff, Stig (författare)
- Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden
-
- Frödin, Ulla (författare)
- Linköpings universitet,Linköping University,Institutionen för medicin och hälsa,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US
-
- Remberger, Mats (författare)
- Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden,Karolinska University Hospital
-
- Höglund, Martin (författare)
- Uppsala University,Uppsala universitet,Hematologi,Uppsala Univ, Sweden
-
- Juliusson, Gunnar (författare)
- Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Lund Univ, Sweden
-
- Stockelberg, Dick (författare)
- Sodra Alvsborgs Hosp, Dept Med & Oncol, Boras, Sweden,South Elfsborg Hospital
-
- Lehmann, Sören (författare)
- Karolinska Institutet,Uppsala University,Karolinska Institute,Karolinska Inst, Sweden; Uppsala Univ, Sweden
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2019
- 2019
- Engelska.
-
Ingår i: Biology of blood and marrow transplantation. - : Elsevier. - 1083-8791 .- 1523-6536. ; 25:9, s. 1770-1778
- Relaterad länk:
-
http://www.bbmt.org/...
-
visa fler...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Secondary AML (s-AML), including AML with an antecedent hematologic disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of patients with AML and is considered to confer a dismal prognosis. The role of allogeneic hematopoietic cell transplantation (HCT) in patients with s-AML and the extent to which HCT is performed in these patients has been little studied to date. We used the population-based Swedish AML Registry comprising 3337 intensively treated adult patients over a 17-year period to study the role of HCT within the group of patients with s-AML as well as compared with patients with de novo AML. HCT was performed in 576 patients (22%) with de novo AML, in 74 patients (17%) with AHD-AML, and in 57 patients (20%) with t-AML. At 5 years after diagnosis, there were no survivors among patients with previous myeloproliferative neoplasms who did not undergo HCT, and corresponding survival for patients with antecedent myelodysplastic syndromes and t-AML was and 2% and 4%, respectively. HCT was compared with chemotherapy consolidation in s-AML using 3 models: (1) a 200-day landmark analysis, in which HCT was favorable compared with conventional consolidation (P = .04, log-rank test); (2) a multivariable Cox regression with HCT as a time-dependent variable, in which the hazard ratio for mortality was 0.73 (95% confidence interval, 0.64 to 0.83) for HCT and favored HCT in all subgroups; and (3) a propensity score matching analysis, in which the 5-year overall survival (OS) and relapse-free survival in patients with s-AML in first complete remission (CR1) was 48% and 43%, respectively, for patients undergoing HCT versus 20% and 21%, respectively, for those receiving chemotherapy consolidation (P = .01 and .02, respectively, log-rank test). Our observational data suggest that HCT improves survival and offers the only realistic curative treatment option in patients with s-AML.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- Secondary AML
- Therapy-related AML
- Allogeneic hematopoietic cell transplantation
- Population-based
- Allogeneic hematopoietic cell transplantation
- Population-based
- Secondary AML
- Therapy-related AML
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, Christe ...
-
Hulegårdh, Erik
-
Garelius, Hege
-
Möllgård, Lars
-
Brune, Mats
-
Wahlin, Anders
-
visa fler...
-
Lenhoff, Stig
-
Frödin, Ulla
-
Remberger, Mats
-
Höglund, Martin
-
Juliusson, Gunna ...
-
Stockelberg, Dic ...
-
Lehmann, Sören
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Biology of blood ...
- Av lärosätet
-
Umeå universitet
-
Uppsala universitet
-
Lunds universitet
-
Karolinska Institutet
-
Linköpings universitet